Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~ ~ Company intends to submit the BLA in third quarter of 2026 ~ LEXINGTON, Mass.
Iovance Biotherapeutics guides for $350M–$370M 2026 revenue with Q2'26 expected to be a record Amtagvi quarter. Read more on ...
Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~ ~ Company intends to submit the BLA in third quarter ...
Introduction Autistic children can experience elevated levels of emotional and behavioural problems, which adversely impact their psychosocial functioning. Positive parenting behaviours can ...
Biology has clever ways to mask the effects of potentially harmful gene mutations. Scientists are investigating how this ...
Introduction Cannabis use is common in the USA and is associated with adverse outcomes across many domains, including sleep difficulties. Targeting insomnia with an evidence-based treatment could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results